Loading clinical trials...
Loading clinical trials...
Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients With Triple Negative Metastatic Breast Cancer
Conditions
Interventions
Decitabine, LBH589, Tamoxifen
Locations
1
United States
Emory University Winship Cancer Institute
Atlanta, Georgia, United States
Start Date
July 1, 2010
Primary Completion Date
January 1, 2014
Completion Date
January 1, 2014
Last Updated
January 26, 2015
NCT04541381
NCT05468034
NCT03137095
NCT07547774
NCT06393374
NCT07040891
Lead Sponsor
Emory University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions